BERG Presents Data Uncovering a Novel Contributor to Parkinson's Disease at Society for Neuroscience 2016 Meeting - Seite 2
"I am very encouraged by the progress of the BERG Interrogative Biology® system as not only did it identify PIG3 as a novel contributor to cell death in PD patients, it also uncovered that a LRRK2 mutation leads to a core abnormality in GBA-related pathways," stated Eric Nestler, MD, PhD, Dean for Academic and Scientific Affairs, Nash Family Professor of Neuroscience and Director of the Friedman Brain Institute at the Icahn School of Medicine at Mount Sinai.
More information on BERG's session 287.09 - Interrogative Biology®identifies p53-inducible gene 3 (PIG3) as a potential contributor to LRRK2-mediated neuronal cell death in Parkinson's Disease: http://www.abstractsonline.com/pp8/index.html#!/4071/presentation/32939
About BERG
BERG is a clinical-stage company disrupting and re-defining the approach to drug discovery, research and development through its Interrogative Biology® platform. Its
platform identifies therapies and biomarkers by applying algorithm- and probability-based artificial intelligence to analyze large numbers of patients' genotypic, phenotypic and other
characteristics. BERG's platform operates at the intersection of biology, technology and artificial intelligence analytics and integrates many data characteristics regarding patients' lifestyles,
demographics and biology. BERG believes this allows the company to better understand patients' disease profiles and consequently to identify and reveal molecular signatures to guide and
accelerate product candidate selection and development. By identifying biomarkers and patient characteristics that are unique to the disease state, BERG is able to identify novel therapeutic
product candidates and develop companion diagnostics to enhance specificity in its drug development process.
BERG has leveraged its Interrogative Biology® platform to develop a robust pipeline of therapeutic product candidates and diagnostics in cancer, diabetes and neurology. Its lead drug, BPM-31510 (IV), has the potential to slow or reverse cancer cell growth by changing a hypothesized fundamental driver of many different types of cancer. BERG has initiated a Phase II clinical trial for BPM-31510 (IV) in advanced pancreatic cancer in combination with a common cancer drug, among other ongoing and planned trials for BPM-31510 (IV) in various oncological indications.
Lesen Sie auch
For additional information, please visit www.BERGhealth.com.